FY2025 · ended Dec 31, 2025 · Revenue $359,700, -10.3% YoY · Filed Mar 26, 2026
Biorestorative Therapies, Inc. (BRTX) files with the SEC under industry code 8090, Services-Misc Health & Allied Services, NEC. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $359,700 and a net loss of $14.2 million. Free cash flow was -$10.9 million.
Revenue (TTM)
$357,870
-8.5% vs year-ago TTM
Net income (TTM)
$-11.06M
+8.6% vs year-ago TTM
Operating cash flow (TTM)
$-11.82M
-36.0% vs year-ago TTM
Free cash flow
$-10.91M
-30.8% vs prior year
EPS (TTM)
$-0.98
+33.7% vs year-ago TTM
Dividend per share
None
Shares outstanding
25.48M
+239.5% vs prior year
Net cash
$10.90M
FY 2023
Operating margin
-3975.0%
FY 2026
Company profile
- Industry
- Services-Misc Health & Allied Services, NEC (SIC 8090)
- Listed as
- BRTX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- NV
- Headquarters
- Melville, NY
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1505497
- Former names
- Stem Cell Assurance, Inc. (until Aug 16, 2011)
Other Services-Misc Health & Allied Services, NEC companies
- Fresenius Medical Care AG FMS
- Davita Inc. DVA
- Sotera Health Co SHC
- Progyny, Inc. PGNY
- agilon health, inc. AGL
- Charming Medical Ltd MCTA
- Viemed Healthcare, Inc. VMD
- Park Dental Partners, Inc. PARK
All 15 Services-Misc Health & Allied Services, NEC companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $359,700 | $401,000 | $145,800 | $119,800 | $46,000 |
| Operating income | -$15.6M | -$11.6M | -$15.2M | -$19.0M | -$26.3M |
| Net income | -$14.2M | -$9.0M | -$10.4M | -$13.2M | -$44.3M |
| Diluted EPS | -$1.58 | -$1.16 | -$2.47 | — | — |
| Operating cash flow | -$10.8M | -$8.2M | -$6.4M | -$5.9M | -$3.3M |
| Free cash flow | -$10.9M | -$8.3M | -$6.6M | -$6.2M | -$3.4M |
| Total assets | $4.1M | $12.3M | $12.6M | $16.4M | $22.5M |
| Total liabilities | — | $3.7M | $2.6M | $6.1M | $856,497 |
| Stockholders' equity | $356,744 | $8.5M | $10.0M | $10.3M | $10.8M |
| Cash and investments | $3.0M | $10.7M | $11.1M | $14.7M | $21.0M |
| Total debt | — | — | $162,317 | $301,645 | $670,700 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change
|
Oct 9, 2026 | Oct 7, 2026 |
| 8-K |
Current report
Officer or director change
|
Sep 11, 2026 | Sep 4, 2026 |
| 8-K/A |
Amended current report
Auditor change, Other events
|
Sep 10, 2026 | Aug 26, 2026 |
| 8-K |
Current report
Change to shareholder rights, Bylaw or fiscal year change, Regulation FD disclosure
|
Sep 2, 2026 | Sep 2, 2026 |
| 8-K |
Current report
Auditor change, Officer or director change
|
Sep 2, 2026 | Aug 26, 2026 |
| 8-K |
Current report
Listing notice
|
Aug 25, 2026 | Aug 21, 2026 |
All 754 Biorestorative Therapies, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.